Andrew J Yee
Overview
Explore the profile of Andrew J Yee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim E, Malespini J, Lei M, Han S, Minsky C, Branagan A, et al.
Blood Adv
. 2025 Mar;
PMID: 40085948
Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes....
2.
Yancy C, Guseh 2nd J, Ghoshhajra B, Falk R, Yee A, Hutchison B
N Engl J Med
. 2025 Jan;
392(4):383-394.
PMID: 39842015
No abstract available.
3.
Waldschmidt J, Sotudeh N, Arora S, Vijaykumar T, Anand P, Stuart H, et al.
Blood Adv
. 2025 Jan;
9(5):1132-1136.
PMID: 39813623
No abstract available.
4.
Nakamoto-Matsubara R, Nardi V, Horick N, Fukushima T, Han R, Shome R, et al.
Blood Cancer J
. 2024 Dec;
14(1):224.
PMID: 39715752
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/refractory and resistant MM is extraosseous extramedullary disease (EMD), whose molecular biology is still not...
5.
Yee A, Laubach J, Campagnaro E, Lipe B, Nadeem O, Friedman R, et al.
Blood Adv
. 2024 Dec;
9(5):1163-1170.
PMID: 39626297
Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM)....
6.
Dimopoulos M, Migkou M, Bhutani M, Ailawadhi S, Kalff A, Walcott F, et al.
Leuk Lymphoma
. 2024 Oct;
65(12):1789-1800.
PMID: 39404476
MEDI2228 is an antibody drug conjugate (ADC) comprised of a fully human B-cell maturation antigen (BCMA) antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer. This phase 1 trial evaluated MEDI2228 in...
7.
Clerc O, Vijayakumar S, Cuddy S, Bianchi G, Canseco Neri J, Taylor A, et al.
JACC Heart Fail
. 2024 Sep;
12(12):1994-2006.
PMID: 39243245
Background: In light-chain (AL) amyloidosis, whether functional status and heart failure-related quality of life (HF-QOL) correlate with cardiomyopathy severity, improve with therapy, and are associated with major adverse cardiac events...
8.
9.
Liu Y, Mo C, Hartley-Brown M, Sperling A, Midha S, Yee A, et al.
Expert Rev Hematol
. 2024 Jul;
17(8):445-465.
PMID: 39054911
Introduction: The treatment of multiple myeloma (MM) is evolving rapidly. Quadruplet regimens incorporating proteasome inhibitors, immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies have emerged as standard-of-care options for newly diagnosed...
10.